Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISR's Cash to Debt is ranked higher than
92% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. ISR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ISR' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.91
ISR's Equity to Asset is ranked higher than
93% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. ISR: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
ISR' s Equity to Asset Range Over the Past 10 Years
Min: -1.18  Med: 0.82 Max: 0.92
Current: 0.91
-1.18
0.92
Interest Coverage No Debt
ISR's Interest Coverage is ranked higher than
89% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.88 vs. ISR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISR' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 7.91
M-Score: -3.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -88.40
ISR's Operating margin (%) is ranked lower than
87% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.54 vs. ISR: -88.40 )
Ranked among companies with meaningful Operating margin (%) only.
ISR' s Operating margin (%) Range Over the Past 10 Years
Min: -360.83  Med: -101.44 Max: -56.56
Current: -88.4
-360.83
-56.56
Net-margin (%) -81.12
ISR's Net-margin (%) is ranked lower than
84% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. ISR: -81.12 )
Ranked among companies with meaningful Net-margin (%) only.
ISR' s Net-margin (%) Range Over the Past 10 Years
Min: -412.14  Med: -99.48 Max: -54.25
Current: -81.12
-412.14
-54.25
ROE (%) -18.15
ISR's ROE (%) is ranked lower than
72% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. ISR: -18.15 )
Ranked among companies with meaningful ROE (%) only.
ISR' s ROE (%) Range Over the Past 10 Years
Min: -659.02  Med: -49.00 Max: -16.5
Current: -18.15
-659.02
-16.5
ROA (%) -16.50
ISR's ROA (%) is ranked lower than
72% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.51 vs. ISR: -16.50 )
Ranked among companies with meaningful ROA (%) only.
ISR' s ROA (%) Range Over the Past 10 Years
Min: -290.54  Med: -41.34 Max: -14.86
Current: -16.5
-290.54
-14.86
ROC (Joel Greenblatt) (%) -55.36
ISR's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.13 vs. ISR: -55.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ISR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -917.05  Med: -94.56 Max: -33.47
Current: -55.36
-917.05
-33.47
Revenue Growth (3Y)(%) -23.70
ISR's Revenue Growth (3Y)(%) is ranked lower than
92% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ISR: -23.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ISR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -50.00 Max: 12.2
Current: -23.7
0
12.2
EBITDA Growth (3Y)(%) -12.60
ISR's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. ISR: -12.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ISR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -26.60 Max: 205.5
Current: -12.6
0
205.5
EPS Growth (3Y)(%) -18.10
ISR's EPS Growth (3Y)(%) is ranked lower than
77% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. ISR: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ISR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.8  Med: -24.95 Max: 233.8
Current: -18.1
-67.8
233.8
» ISR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ISR Guru Trades in Q4 2014

Jeff Auxier 14,218 sh (unchged)
» More
Q1 2015

ISR Guru Trades in Q1 2015

Jeff Auxier 14,218 sh (unchged)
Jeff Auxier 14,218 sh (unchged)
» More
Q2 2015

ISR Guru Trades in Q2 2015

Jeff Auxier 14,218 sh (unchged)
» More
Q3 2015

ISR Guru Trades in Q3 2015

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 21.01
ISR's Forward P/E is ranked lower than
54% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.41 vs. ISR: 21.01 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.03
ISR's P/B is ranked higher than
60% of the 254 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. ISR: 2.03 )
Ranked among companies with meaningful P/B only.
ISR' s P/B Range Over the Past 10 Years
Min: 0.31  Med: 3.76 Max: 77
Current: 2.03
0.31
77
P/S 8.31
ISR's P/S is ranked lower than
99.99% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.94 vs. ISR: 8.31 )
Ranked among companies with meaningful P/S only.
ISR' s P/S Range Over the Past 10 Years
Min: 0.56  Med: 5.54 Max: 285
Current: 8.31
0.56
285
Current Ratio 16.48
ISR's Current Ratio is ranked higher than
97% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.66 vs. ISR: 16.48 )
Ranked among companies with meaningful Current Ratio only.
ISR' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 6.72 Max: 24.59
Current: 16.48
0.82
24.59
Quick Ratio 15.98
ISR's Quick Ratio is ranked higher than
97% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. ISR: 15.98 )
Ranked among companies with meaningful Quick Ratio only.
ISR' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 5.71 Max: 24.21
Current: 15.98
0.68
24.21
Days Inventory 34.68
ISR's Days Inventory is ranked higher than
94% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 130.74 vs. ISR: 34.68 )
Ranked among companies with meaningful Days Inventory only.
ISR' s Days Inventory Range Over the Past 10 Years
Min: 7.7  Med: 39.96 Max: 64.02
Current: 34.68
7.7
64.02
Days Sales Outstanding 85.54
ISR's Days Sales Outstanding is ranked lower than
76% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 64.59 vs. ISR: 85.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.32  Med: 65.90 Max: 109.1
Current: 85.54
50.32
109.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.48
ISR's Price/Net Cash is ranked higher than
74% of the 77 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.17 vs. ISR: 3.48 )
Ranked among companies with meaningful Price/Net Cash only.
ISR' s Price/Net Cash Range Over the Past 10 Years
Min: 1  Med: 9.20 Max: 157.5
Current: 3.48
1
157.5
Price/Net Current Asset Value 3.04
ISR's Price/Net Current Asset Value is ranked higher than
76% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.42 vs. ISR: 3.04 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.71  Med: 6.36 Max: 175
Current: 3.04
0.71
175
Price/Tangible Book 2.03
ISR's Price/Tangible Book is ranked higher than
69% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.39 vs. ISR: 2.03 )
Ranked among companies with meaningful Price/Tangible Book only.
ISR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.35  Med: 3.90 Max: 72.5
Current: 2.03
0.35
72.5
Price/Median PS Value 1.66
ISR's Price/Median PS Value is ranked lower than
82% of the 253 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISR: 1.66 )
Ranked among companies with meaningful Price/Median PS Value only.
ISR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 1.04 Max: 46.36
Current: 1.66
0.11
46.36
Earnings Yield (Greenblatt) (%) -14.69
ISR's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. ISR: -14.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ISR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -14.69  Med: 317.80 Max: 16057.5
Current: -14.69
-14.69
16057.5

More Statistics

Revenue(Mil) $5
EPS $ -0.08
Beta1.41
Short Percentage of Float8.37%
52-Week Range $0.55 - 3.79
Shares Outstanding(Mil)55.01

Analyst Estimate

Jun16 Jun17 Jun18
Revenue(Mil) 14 22 31
EPS($) 0.07 0.17 0.26
EPS without NRI($) 0.07 0.17 0.26

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
IsoRay Inc was organized under Minnesota law in 1983. The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. In 2003, the Company obtained clearance from the FDA for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer; and pancreatic cancer. The brachytherapy seed form of Cesium-131 may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. In March 2011, the Company received clearance to commercially deliver Proxcelan Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands into Europe. Its products include Proxcelan Cesium-131, GliaSite RTS is the only FDA cleared balloon catheter device used in the treatment of brain cancer. The GliaSite RTS and the Company's brachytherapy products used in non-prostate applications typically compete with external beam radiation therapy (EBRT), which can be provided as conventional or intensity modulated radiation therapy, or as stereotactic radiosurgery, a technique that delivers high doses of radiation to a target in a much lower number of sessions than other forms of EBRT. The Company's present and future activities in the development, manufacture and sale of cancer therapy products are subject to extensive laws, regulations, regulatory approvals and guidelines.
» More Articles for AMEX:ISR

Headlines

Articles On GuruFocus.com
IsoRay Inc. Reports Operating Results (10-K) Sep 28 2010 
IsoRay Inc. Reports Operating Results (10-Q) May 12 2010 
IsoRay Inc. Reports Operating Results (10-Q) Nov 12 2009 
IsoRay Inc. Reports Operating Results (10-Q/A) Sep 02 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jan 15 2016
IsoRay Appoints Thomas LaVoy as CEO to Take Office on February 15 Jan 14 2016
IsoRay Chairman and CEO Dwight Babcock to Retire Jan 13 2016
Clinical Study Discusses Cost Effectiveness of Surgical Resection and IsoRay's Cesium-131... Jan 13 2016
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jan 12 2016
IsoRay Chairman and CEO Dwight Babcock to Retire Jan 07 2016
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 31 2015
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 21 2015
IsoRay, Inc. Earnings Analysis: Q1, 2016 By the Numbers Dec 17 2015
Cesium-131 Minimizes the Risk of Radiation-Induced Injury Dec 16 2015
Cesium-131 Minimizes the Risk of Radiation-Induced Injury Dec 16 2015
Weill Cornell Medical Clinical Study Demonstrates Cesium-131 Brachytherapy Seeds on a String... Dec 16 2015
Weill Cornell Clinical Study Notes 12/14/2015 Dec 14 2015
Weill Cornell Clinical Study Notes Cesium-131 Brachytherapy Can Provide a Viable Alternative to... Dec 14 2015
ISORAY, INC. Financials Dec 08 2015
Isoray Reports First Quarter Fiscal 2016 Financial Results Nov 10 2015
ISORAY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 10 2015
IsoRay Reports First Quarter Fiscal 2016 Financial Results Nov 10 2015
ISORAY, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2015
Isoray’s Proprietary Cesium-131 Product Line Will Be on Display at the American Society for... Oct 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK